FY2026 EPS Estimate for Palisade Bio Lowered by Analyst

Palisade Bio logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Brookline Capital Markets cut its FY2026 EPS forecast to a loss of $0.24 per share from a loss of $0.21, bringing it in line with consensus. It projects losses through 2029 before earnings turn positive at $0.44 per share in 2030.
  • Palisade Bio reported a quarterly loss of $0.07 per share, missing analysts’ estimate of a $0.06 loss by $0.01.
  • Analyst views are mixed: MarketBeat reports a consensus “Buy” rating and $9 average price target, while HC Wainwright lowered its target to $5 and Wall Street Zen downgraded the stock to “Strong Sell.” Shares opened at $1.12.
  • Interested in Palisade Bio? Here are five stocks we like better.

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Research analysts at Brookline Capital Markets cut their FY2026 earnings estimates for Palisade Bio in a note issued to investors on Wednesday, November 11th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of ($0.24) per share for the year, down from their prior estimate of ($0.21). The consensus estimate for Palisade Bio's current full-year earnings is ($0.24) per share. Brookline Capital Markets also issued estimates for Palisade Bio's Q4 2026 earnings at ($0.07) EPS, FY2027 earnings at ($0.29) EPS, FY2028 earnings at ($0.35) EPS, FY2029 earnings at ($0.48) EPS and FY2030 earnings at $0.44 EPS.

A number of other research analysts have also commented on PALI. HC Wainwright decreased their price objective on Palisade Bio to $5.00 and set a "buy" rating on the stock in a research report on Wednesday, November 11th. Oppenheimer restated an "outperform" rating on shares of Palisade Bio in a research report on Wednesday, October 21st. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Palisade Bio in a research note on Monday, October 12th. Raymond James Financial assumed coverage on Palisade Bio in a report on Thursday, October 8th. They issued an "outperform" rating and a $6.00 price target on the stock. Finally, Wall Street Zen lowered Palisade Bio from a "sell" rating to a "strong sell" rating in a research report on Saturday. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $9.00.

Check Out Our Latest Analysis on Palisade Bio

Palisade Bio Price Performance

Shares of Palisade Bio stock opened at $1.12 on Monday. The firm has a 50 day simple moving average of $1.48 and a 200 day simple moving average of $1.82. Palisade Bio has a fifty-two week low of $1.08 and a fifty-two week high of $2.85. The firm has a market cap of $200.79 million, a P/E ratio of -2.33 and a beta of 1.61.

Palisade Bio (NASDAQ:PALI - Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01).

Institutional Trading of Palisade Bio

Institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its stake in shares of Palisade Bio by 19.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 81,000 shares of the company's stock valued at $117,000 after purchasing an additional 13,110 shares during the period. Legal & General Group Plc bought a new position in shares of Palisade Bio in the 2nd quarter worth $30,000. CTC Alternative Strategies Ltd. bought a new position in shares of Palisade Bio in the 1st quarter worth $31,000. WINTON GROUP Ltd grew its stake in shares of Palisade Bio by 180.2% during the second quarter. WINTON GROUP Ltd now owns 32,227 shares of the company's stock worth $67,000 after purchasing an additional 20,727 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Palisade Bio during the second quarter worth $54,000. Institutional investors and hedge funds own 11.79% of the company's stock.

Latest Palisade Bio News

Here's some of the latest news about PALI:

Palisade Bio Company Profile

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn's disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

See Also

Earnings History and Estimates for Palisade Bio (NASDAQ:PALI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Palisade Bio Right Now?

Before you consider Palisade Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palisade Bio wasn't on the list.

While Palisade Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines